以色列将灭活甲肝疫苗纳入儿童常规免疫规划18年后的甲型肝炎病毒人群血清保护率
以色列自1999年起将甲肝灭活疫苗纳入儿童常规免疫规划。本研究对比2011-2012年招募的儿童期接种前出生队列(BCV)士兵339人与2017年招募的接种后出生队列(ACV)新兵295人的血清阳性率,BCV组为35%,ACV组为68%(P<0.0001)。作者认为现有发现不支持在进一步评估前停止对高危人群接种甲肝疫苗。
要点
- 儿童期接种后出生队列(ACV)甲肝血清阳性率为68%,接种前出生队列(BCV)为35%(P<0.0001)。
- ACV组血清阳性率可用于评估疫苗接种规划对人群的影响。
- 作者认为现有发现不支持在进一步评估前停止对高危人群接种甲肝疫苗。
核心结论
- 儿童期接种后出生队列(ACV)甲肝血清阳性率为68%,显著高于接种前出生队列(BCV)的35%(P<0.0001)。
- 作者认为现有发现不支持在进一步评估前停止对高危人群接种甲肝疫苗。
研究设计与样本
- 血清学调查,分析339名BCV组新兵和295名ACV组新兵的数据。
- BCV组为2011-2012年招募、出生于儿童期接种引入前的士兵;ACV组为2017年招募、出生于儿童期接种引入后的新兵。
主要发现
- BCV组血清阳性率为35%,ACV组为68%(P<0.0001)。
- ACV组受试者的血清阳性率可用于评估疫苗接种规划对人群的影响。
关键数值与推荐
- BCV组血清阳性率35%,ACV组68%,两组比较P<0.0001。
临床怎么用
- 作者认为现有发现不支持在进一步评估前停止对高危人群接种甲肝疫苗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccine against Hepatitis A virus (HAV) is part of the routine vaccination schedule in Israel since 1999. As of 2016, new recruits to the Israel Defense Forces should have been vaccinated in their childhood. This sero-survey aimed to determine immunity against HAV 18 years after childhood vaccination, and to re-evaluate the need for HAV vaccination booster upon recruitment. Two populations were studied: soldiers who were recruited during 2011-2012, who belonged to birth cohorts before childhood vaccination (BCV) was introduced; and recruits from 2017, who belonged to birth cohorts after childhood vaccination (ACV) was introduced. Data on 339 BCV recruits and 295 ACV recruits were analyzed. Seropositivity was 35% in the BCV group and 68% in the ACV group (P < 0.0001). Seropositivity rates among ACV subjects enable evaluation of the vaccination program's impact on the population. Our findings do not support discontinuation of HAV vaccination of at risk groups until further evaluation.
引用
- Galor I, Perry Markovich M, Wolf D, et al. Population seroprotection against hepatitis a virus in Israel 18 years after introduction of inactivated vaccine into the routine childhood vaccination schedule. Vaccine. 2020. PMID: 31932135. doi:10.1016/j.vaccine.2019.12.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。